Sonpavde, Guru <br/><br/>
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.  [electronic resource] 

 -  Urologic oncology   
 - 682-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2496 
<br/><br/><label>Standard No.: </label>10.1016/j.urolonc.2009.09.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Aged<br/>Aged, 80 and over<br/>Androgen Antagonists--therapeutic use<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Azacitidine--therapeutic use<br/>Castration<br/>DNA Methylation--drug effects<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm--drug effects<br/>Humans<br/>Kaplan-Meier Estimate<br/>Long Interspersed Nucleotide Elements--genetics<br/>Male<br/>Middle Aged<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood